Antibody-based Novel Target Immunotherapy in Hematological Malignancy

Monoclonal (mAbs) and bispecific antibodies (BsAbs), including tri-specific antibodies (TsAbs), represent the forefront of immunotherapy, harnessing the body's immune system to target and eliminate cancer cells. These therapies specifically activate immune cells, such as T cells and natural killer (NK) cells, to attack malignant cells by targeting tumor-specific antigens. Despite the transformative impact of mAbs on cancer treatment, issues like resistance and disease progression through alternative pathways persist, underscoring the necessity for more effective strategies. TsAbs and BsAbs, which can engage multiple antigens, offer increased therapeutic precision and potency, potentially overcoming these hurdles.

This Research Topic aims to advance our understanding of antibody-based therapies for hematological malignancies and improve therapeutic outcomes. Specifically, it seeks to explore innovative strategies combining mAbs, BsAbs, and TsAbs with other treatments, such as immune checkpoint inhibitors, to address resistance mechanisms and enhance efficacy. Additionally, we aim to investigate the latest developments in antibody technology, including improved target identification and the optimization of pharmacokinetic properties which facilitate their application in clinical settings.

To gather further insights into the nuances of antibody-mediated immunotherapy, we welcome articles addressing, but not limited to, the following themes:
o Development and clinical evaluation of novel mAbs, BsAbs, and TsAbs for hematological malignancies.
o Mechanisms of action of antibody-based therapies and their immune modulation in hematological cancers.
o Dynamics of the immune microenvironment in response to antibody treatments in hematological conditions.
o Cutting-edge combination therapies integrating mAbs, BsAbs, and TsAbs with other cancer treatments.
o Identification and validation of new biomarkers for predicting treatment response and efficacy, and tailoring antibody-based treatments.

Keywords: bispecific antibodies, acute lymphoblastic leukemia, acute myeloid leukemia，myelodysplastic syndrome, lymphoma, multiple myeloma, immunotherapy

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.